Sign In
Buy ALBO
$44.15
+0 (+0%)
At Close: May 26, 2023
Albireo Pharma (ALBO) Received its Third Buy in a Row
02:26pm, Friday, 27'th Mar 2020
After Wedbush and Needham gave Albireo Pharma (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced eff
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) * Masimo Corporation (NASDAQ: MASI)Down In The Dum
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
Albireo Completes Enrollment in Phase 2 Study of Elobixibat in NASH/NAFLD
12:30pm, Tuesday, 10'th Mar 2020
On track to report topline data mid-2020 BOSTON, March 10, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing.
Albireo Pharma, Inc. Just Reported And Analysts Have Been Cutting Their Estimates
10:05am, Wednesday, 04'th Mar 2020
Albireo Pharma, Inc. (NASDAQ:ALBO) last week reported its latest yearly results, which makes it a good time for...
H.C. Wainwright Maintains a Buy Rating on Albireo Pharma (ALBO)
12:15pm, Tuesday, 03'rd Mar 2020
H.C. Wainwright analyst
Ed Arce
maintained a
Buy
rating on Albireo Pharma (
ALBO
–
Research Report
) today and set a price target of
$62.00
. The company’s shares closed last Monday at $24.22.
Acc
Albireo Reports Fourth Quarter and Year-End 2019 Financial Results, and Provides Business Update
12:30pm, Monday, 02'nd Mar 2020
— Phase 3 odevixibat PFIC trial fully enrolled — — Initiating pivotal trials in biliary atresia first half of 2020 and Alagille syndrome by year end — — Management to.
The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off
07:52pm, Saturday, 29'th Feb 2020
Biotech stocks came under significant weakness along with the broader market in the week ended Feb. 28. Despite fears the COVID-19 epidemic will likely drag global growth, the viral outbreak proved ad
Did Changing Sentiment Drive Albireo Pharma's (NASDAQ:ALBO) Share Price Down By 17%?
02:12pm, Thursday, 27'th Feb 2020
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if...
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced its support for Rare Disease Day 2020 and reaffirms its comm
Albireo to Present at Cowen and Company 40th Annual Health Care Conference
01:30pm, Wednesday, 26'th Feb 2020
BOSTON, Feb. 26, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
Albireo to Report Fourth Quarter and Year-End 2019 Financial Results on March 2
01:30pm, Monday, 24'th Feb 2020
BOSTON, Feb. 24, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
NASH: The Second Wave
11:29pm, Thursday, 20'th Feb 2020
Although the first wave (the companies with drugs at Phase-3) is already at the finish line, the effectiveness indicators of these drugs are far from being stro
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the completion of its previously announced underwritten pub
